Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2009—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds

Definitions

• PPIs protein protein interactions
• inhibitors of PPIs are proteins rather than small-molecule inhibitors.
• therapeutic monoclonal antibodies mAbs
• Therapeutic mAbs are costly to manufacture, they require administration by injection, and can illicit an immune-response in the patient. For these reasons the development of small-molecule inhibitors of PPIs remains of interest.
• WT TTR soluble protein transthyretin
• WT TTR dimers can misfold into amyloidogenic monomers. The formation of amyloidogenic monomers has observed with WT TTR as well as more than 100 different mutated variants. Research has shown that stabilizing the tetrameric form of TTR inhibits the misfolding of amyloidogenic monomers and subsequent TTR amyloid formation.
• the present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
• the tablet formulation is coated with a coating agent.
• FIG. 1 illustrates the process flow diagram for preparing the AG10 formulations described in Example 2.
• FIG. 2 shows images of the AG10 HC1 coated tablets prepared in Example 2.
• FIG. 3 show the dissolution profile for AG10 solid tablets formulations described in
• FIG. 4 illustrates the process flow diagram for preparing the AG10 formulations described in Example 3.
• FIG. 5 illustrates the process flow for aqueous coating suspension preparation or preparing the AG10 formulations described in Example 3.
• FIG. 6 shows images illustrating the lack of tablet edge’s erosion after friability test for L018A (High hardness, Left), and L018B (Middle hardness, Right) (at 33.0% AG10).
• FIG. 7 shows images of major tablet edge’s erosion after friability test for L016 (Left), and for L017 (Right) (Both formulations have a 40% AG10 load and maximum hardness).
• FIG. 8 illustrates the process Flow Diagram for the 33% AG10 HC1 Tablets described in Example 4.
• FIG. 9 illustrates the process Flow Diagram for the 66.7% AG10 HC1 Tablets described in Example 4.
• FIG. 10 shows the dissolution profile of 33.3% AG10 HC1 tablets after storage under 40°C/75% RH Conditions.
• T 0 (open triangles);
• T 1 Month (open diamonds)
• T 3 Months (filled circles);
• T 6 months (filled squares).
• the present disclosure is based, in part, on the discovery that formulations containing 40% or more AG10 can be successfully prepared as tablets. These tablets are particularly well suited for administration to human and animal subjects alike because these amounts meet the necessary stability and pharmacokinetic requirements for oral formulations. Other formulations, such as capsules, fail to meet these needs.
• the term "about” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In some embodiments, the term “about” means within a standard deviation using measurements generally acceptable in the art. In some embodiments, about means a range extending to +/- 10% of the specified value. In some embodiments, about means the specified value.
• tablette refers to solid pharmaceutical formulations with and without a coating.
• tablette also refers to tablets having one, two, three or even more layers, wherein each of the before mentioned types of tablets may be without or with one or more coatings.
• tablets of the present disclosure can be prepared by roller compaction or other suitable means known in the art.
• the term“tablet” also comprises mini, melt, chewable, effervescent and orally disintegrating tablets. Tablets include AG10 and at least and one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
• a coating agent is also included. For the purposes of calculating percent weight of the tablet formulation, the amount of coating agent is not included in the calculation. That is, the percent weights reported herein are of the uncoated tablet.
• salt refers to acid or base salts of the compounds of the present disclosure.
• pharmaceutically acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, l7th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference. III. Embodiments of the Disclosure
• AG10 is a compound having the formula:
• a pharmaceutically acceptable salt of AG10 is corresponds to Formula I.
• X is a pharmaceutically acceptable anion of a protic acid.
• a variety of protic acids are suitable for making a pharmaceutically acceptable salt of
• protic acids useful in the present disclosure include hydrochloric acid, hydrobromic acid, sulfonic acid, tosylic acid (p- toluenesulfonic acid), methanesulfonic acid, nitric acid, or acetic acid.
• protic acids useful in the present disclosure include hydrochloric acid, hydrobromic acid, sulfonic acid, tosylic acid (p- toluenesulfonic acid), methanesulfonic acid, nitric acid, or acetic acid.
• compositions of a protic acid include chloride (CT), bromide (Br), sulfonate (HS(0)20 ), tosylate (TsO ), mesylate (MsO ), nitrate (NO3 ) and acetate
• the pharmaceutically acceptable anion of a protic acid is mesylate.
• the pharmaceutically acceptable anion of a protic acid is tosylate.
• the pharmaceutically acceptable anion of a protic acid is chloride, and the pharmaceutically acceptable salt of Formula I is represented by Formula (la)
• compositions of Formula I can be produced using a number of conventional means in the art.
• the free acid form of a compound of Formula I may be contacted with a stoichiometric amount of the appropriate acid in water, an organic solvent, or a mixture of the two.
• pharmaceutically acceptable salts of Formula I are made in nonaqueous media such as an ether, ethyl acetate, ethanol, isopropanol, or acetonitrile.
• the pharmaceutically acceptable salts of Formula I are made by dissolving a compound of Formula IX in water, adding a suitable amount of HX to form a mixture, and adding a nonaqueous solvent, such as the nonaqueous media described above to crystallize the salt.
• a suitable amount of HX is a stoichiometric amount. It is understood the HX comprises a hydrogen and an X is a pharmaceutically acceptable anion of a protic acid as defined above.
• the tablet formulations of the present disclosure can include, for example, about 40 to 85 or about 50 to 75% by weight of AG10 or a pharmaceutically acceptable salt thereof.
• the tablet formulations contain about 50% to 70% by weight of AG10 or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet formulations contain about 50% by weight of AG10 or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet formulations contain about 66.7% by weight of AG10 or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet formulations contain about 75% by weight of AG10 or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet formulations contain about 80% by weight of AG10 or a pharmaceutically acceptable salt thereof. In some embodiments, the tablet formulations contain about 85% by weight of AG10 or a pharmaceutically acceptable salt thereof.
• the amount of AG10 or a pharmaceutically acceptable salt thereof, in a tablet formulation can be about 0.1 to about 500 mg, about 0.1 to about 250 mg, or about 0.1 to about 100 mg. In some embodiments, the amount of AG10 present in a tablet formulation is about 10, 25, 50, 100, 200, 300, 400, or 500 mg. In some embodiments, the amount of AG10 present in a tablet formulation is about 50, 100, 200, or 400 mg. In some embodiments, the total weight (e.g., active ingredients plus excipients - not including coating) of the tablet formulation is about 50 to about 1500 mg. For example, the total weight of the solid dosage form is about 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or 1500 mg.
• the tablet formulations of the present disclosure can include at least one ingredient selected from one or more fillers, one or more binders, one or more disintegrates, and one or more lubricants or other ingredient.
• the tablet formulation comprises one or more excipients selected from a high grade microcrystalline filler, an inorganic salt filler, a disintegrant, and a lubricant.
• the tablet formulations of the present disclosure include one or more fillers. Suitable fillers are described below.
• the one or more fillers are present in an amount of about 1 to 60, 5 to 55, 10 to 50, or 15 to 45% by weight. In some embodiments, one or more fillers are present in about 42.5% by weight. In some embodiments, one or more fillers are present in about 25.8% by weight. In some
• one or more fillers are present in about 17.5% by weight.
• tablet formulations of the present disclosure include one to three fillers. In some embodiments, tablet formulations of the present disclosure include one to two fillers. In some embodiments, tablet formulations of the present disclosure include two fillers.
• Suitable fillers include, for example, oligosaccharides (e.g., lactose), sugars, starches, modified starches, sugar alcohols (e.g. mannitol, sorbitol, xylitol, lactitol), inorganic salts, cellulose derivatives (e.g. microcrystalline cellulose, silicified microcrystalline cellulose, cellulose, hypromellose), calcium sulfate, aluminum and magnesium silicate complexes and oxides, and the like.
• inorganic salt fillers include a phosphate salt, such as dibasic calcium phosphate dehydrate, salts of sulfates, and silicon dioxide.
• the one or more fillers include cellulose derivatives or alkaline earth metal salts of chloride, phosphates, sulfates, and the like. In some embodiments, the one or more fillers include a cellulose derivative and an inorganic salt. In some embodiments, the one or more fillers are microcrystalline cellulose and silicon dioxide. In some embodiments, the one or more fillers are microcrystalline cellulose. In some embodiments, the
• microcrystalline cellulose is a high grade microcrystalline cellulose.
• a high grade microcrystalline cellulose is a cellulose derived product that has specific properties that are not the dominant features in more standard preparations of microcrystalline cellulose.
• a high grade microcrystalline cellulose is characterized by cellulose polymers with spherical morphology and porous structure. These properties are found in UF grade microcrystalline cellulose from
• CEOLUSTM e.g. UF-702 and UF-711
• UF-702 e.g. UF-702 and UF-711
• similar available products e.g. UF-702 and UF-711
• a high grade microcrystalline cellulose is characterized by cellulose polymers with needle-like particle shape. These properties are found in KG grade microcrystalline cellulose from CEOLUSTM (e.g. KG-802 and KG-1000).
• the high grade cellulose filler can be present in an amount of about 1 to 60% by weight. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 5 to 55% by weight. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 10 to 50% by weight. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 15 to 45% by weight.
• the high grade microcrystalline cellulose is present in an amount of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45% by weight. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 17%. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 26%. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 42%.
• the tablet formulations of the present disclosure include one or more binders. Suitable binders are described below. In some embodiments, the one or more binders are present in an amount of about 0.5 to 15, about 0.5 to 10, or about 1 to 10% by weight. In some embodiments, the one or more binders are present in an amount of about 3 to 8% by weight. In some embodiments, the one or more binders are present in an amount of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% by weight. In some embodiments, the one or more binders are present in about 5% by weight.
• tablet formulations of the present disclosure include one to three binders. In some embodiments, tablet formulations of the present disclosure include one binder.
• Suitable binders include, for example, povidone, lactose, starches, modified starches, sugars, gum acacia, gum tragacanth, guar gum, pectin, wax binders,
• Non-cellulosic binders include polymeric and other binders lacking a cellulose backbone. Examples of non-cellulosic binders include povidone, lactose, starches, modified starches, gums, guar gum, pectin, waxes, gelatins, alginates, and the like.
• formulations contain a non-cellulosic binder such as povidone or copovidone. In some embodiments, the non-cellulosic binder is copovidone.
• the tablet formulations of the present disclosure include one or more disintegrants. Suitable disintegrants are described below.
• the one or more disintegrants are present in an amount of about 1 to 15, about 1 to about 12, or about 1 to about 10% by weight.
• one or more disintegrants are present in about 3-8% by weight.
• the formulations contain about 3, 4, 5, 6, 7, or 8% by weight of disintegrant.
• the formulations contain about 5% by weight of disintegrant.
• the formulations contain about 6% by weight of disintegrant.
• tablet formulations of the present disclosure include one to three disintegrants. In some embodiments, tablet formulations of the present disclosure include one disintegrant.
• Suitable disintegrants include, for example, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, sodium starch glycolate, com starch.
• the formulations contain a disintegrant such as sodium starch glycolate or crospovidone.
• the disintegrant is croscarmellose sodium.
• the tablet formulations of the present disclosure include one or more lubricants. Suitable lubricants are described below. In some embodiments, the one or more lubricants are present in an amount of about 0.1 to 8, 0.5 to 5, 0.5 to 3% by weight.
• one or more lubricants are present in an amount of about 0.5, 0.75, 1, 1.5, 2, 3, 4, or 5% by weight. In some embodiments, one or more lubricants are present in an amount of about 2% by weight. In some embodiments, one or more lubricants are present in an amount of about 1.5% by weight.
• tablet formulations of the present disclosure include one to three lubricants. In some embodiments, tablet formulations of the present disclosure include one lubricant.
• Suitable lubricants include, for example, magnesium stearate, stearic acid, palmitic acid, calcium stearate, talc, camauba wax, hydrogenated vegetable oils, mineral oil, polyethylene glycols, and sodium stearyl fumarate.
• the one or more lubricants are magnesium stearate and/or sodium stearyl fumarate. In some embodiments, the one or more lubricants is magnesium stearate.
• the tablet is coated with a coating agent.
• Suitable coating agents include ethylcellulose, polymethacrylates, as well as coating products sold by
• the coating agent is Opadry Clear, Opadry Blue 13B50579, Opadry White 33628707, Opadrya QX 321A180025, or Opadry II (33G28707).
• the coating agent is Opadry White 33628707. In some embodiments the coating agent is Opadry QX 321 Al 80025. In some embodiments the coating agent is Opadry II (33G28707).
• the amount of coating agent is not included in the calculation. That is, the percent weights reported herein are of the uncoated tablet.
• the tablet formulation contains about 40 to 85% by weight of AG10 or a pharmaceutically acceptable salt thereof; about 5 to 55% by weight of one or more fillers; about 0 to 15% by weight of one or more binders; about 1 to 15% by weight of one or more disintegrants; and about 0.1 to 8% by weight of one or more lubricants.
• the noted formulation includes a coating agent.
• the tablet formulation contains about 50 to 75% by weight of AG10 or a pharmaceutically acceptable salt thereof; about 10 to 50% by weight of one or more fillers; about 3 to about 8% by weight of one or more disintegrants; and 0.5 to 3% by weight of one or more lubricants.
• the noted formulation includes a coating agent.
• the tablet formulation contains about 50% by weight of AG10 or a pharmaceutically acceptable salt thereof; about 42.5% by weight of one or more fillers; about 6% by weight of a disintegrant; and about 1.5% by weight of a lubricant.
• the noted formulation includes a coating agent.
• the tablet formulation contains about 66.7% by weight of AG10 or a pharmaceutically acceptable salt thereof; about 25.8% by weight of one or more fillers; about 6% by weight of a disintegrant; and about 1.5% by weight of a lubricant.
• the noted formulation includes a coating agent.
• the tablet formulation contains about 75% by weight of AG10 or a pharmaceutically acceptable salt thereof; about 17.5% by weight of one or more fillers; about 6% by weight of a disintegrant; and about 1.5% by weight of a lubricant.
• the noted formulation includes a coating agent.
• the tablet formulation of the present disclosure are at least 75% dissolved after 10 minutes in a solution of 0.1N HC1 at 37 ⁇ 0.5 °C in an Apparatus-II (Paddles) with a paddle speed of about 50 rpm. In some embodiments, the tablet formulation of the present disclosure are at least 85% dissolved after 10 minutes in a solution of 0.1N HC1 at 37 ⁇ 0.5 °C in an Apparatus-II (Paddles) with a paddle speed of about 50 rpm.
• the tablet formulation of the present disclosure are at least 95% dissolved after 10 minutes in a solution of 0.1N HC1 at 37 ⁇ 0.5 °C in an Apparatus-II (Paddles) with a paddle speed of about 50 rpm.
• the tablet is tested was prepared within a week of the dissolution test.
• the tablet is tested was prepared at least a month before performing the dissolution test.
• the tablet is tested was prepared at least a three months before performing the dissolution test.
• the tablet is tested was prepared at least six months before performing the dissolution test. In some embodiments, the tablet was incubated for one month at 25°C with 60% relative humidity (RH) before performing the dissolution test. In some embodiments, the tablet was incubated for two months at 25°C with 60% relative humidity (RH) before performing the dissolution test. In some embodiments, the tablet was incubated for three months at 25°C with 60% relative humidity (RH) before performing the dissolution test. In some embodiments, the tablet was incubated for one month at 40°C with 75% relative humidity (RH) before performing the dissolution test. In some embodiments, the tablet was incubated for three months at 40°C with 75% relative humidity (RH) before performing the dissolution test. In some embodiments, the tablet was incubated for six months at 40°C with 75% relative humidity (RH) before performing the dissolution test. IV. Examples
• the pharmacokinetics of AG10 were also determined following oral administration in non-naive male and female beagle dogs (Study No. 2).
• Groups 1 and 2 received 5 mg/kg and 20 mg/kg AG10 in 0.5% methylcellulose (MC) formulations respectively.
• Group 3 animals received 20 mg/kg AG10 in gelatin capsule form.
• Blood samples were collected at pre-dose and approximately 2, 4, 6, 8, 12, and 24 hours post-dose. Plasma samples were assayed for AG10 by LC- MS/MS.
• Plasma exposures (AUC0-24) of AG10 in dogs administered 20 mg/kg AG10 as a suspension in 0.5% methylcellulose were similar to those obtained in Study No. 1 (Table 1).
• Plasma exposures of AG10 were also similar in dogs which were administered the same dose of AG10 either as a suspension in 0.5% methylcellulose or as a gelatin capsule without any excipients.
• AG10 was administered orally to 4 male beagle dogs each as a 50 mg tablet, 200 mg tablet, and a 200 mg capsule (No. 3). Blood samples were collected at pre-dose and approximately 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose. Plasma samples were assayed for AG10 by LC-MS/MS. The C max and AUCo-i nf values for dogs dosed with 200 mg tablets and 200 mg capsules were not significantly different (P ⁇ 0.05) as determined by an unpaired t-test (P values of 0.0788 and 0.0995 for C max and AUCo-i nf respectively).
• time to maximal concentration was 0.44 ⁇ 0.38 hr in study No. 1 and 2.5 ⁇ 1 hr in study No. 2.
• Tmax 2 ⁇ 0 hr
• study No. 3 even though the maximal exposure of AG10 tablets was comparable to that of the capsule, animal to animal variability in absorption of AG10 was greater in the four animals orally dosed with capsule containing excipients.
• time to maximal concentration was 0.500 ⁇ 0 hr
• for the 200 mg tablets was at 1.00 ⁇ 0 hr.
• Tmax was more variable at 1.38 ⁇ 0.750 hr.
• Table 2 provides information on the relative amounts of components used in each formulation.
• Tablets were prepared using the general diagram provided in FIG. 1.
• Table 3 below, provides an exemplary amounts used in formulating a tablet formulation with 66.7% AG10 HC1 (Batch 2), and Table 4 and Table 5 provide a list of equipment used and a summary of the steps performed to prepare the tablet formulation. Similar processes were performed when preparing Batch 1 and Batch 3, referenced in Table 2.
• FIG. 2 A picture of a 50% (w/w) and a 66.7 (w/w) AG10 HC1 coated tablets are shown in FIG. 2.
• the 50 % tablet was compressed with 8 x 17.5 mm capsule shaped tooling, while 66.7 % tablet was compressed at 7.5 x 15 mm capsule tooling.
• Physical properties of the two displayed tablets are summarized in Table 6. Table 6: Summary of Physical Properties
• Friability of the tablets was evaluated according to USP method ⁇ 1216> from the percentage weight loss of NLT 6.5g of tablets tumbled in a friabilator (model EF-2, Electrolab) for 100 rounds at 25 rpm. The tablets were dedusted, and the loss in weight caused by fracture or abrasion was recorded as the percentage weight loss. Friability below 1% is considered acceptable.
• FIG. 3 shows the dissolution profiles of a 50% (w/w) and a 66.7 (w/w) AG10 HC1 coated tablets. The dissolution experiment was performed with no significant incubation time after the tablet was formulated. As seen in FIG. 3 dissolution reached 100% released within 10 minutes for both tablets.
• Example 3 Tablet Formulations Exceeding 33.3% AGIO Exhibited Tablet Erosion During Friability Test
• each of the above referenced formulations were prepared as 200 mg tablets and underwent a friability test as described in Example 2.
• Tablets from L018A and L018B prepared at 33.0% drug load (and compressed at high and middle hardness kP values, respectively) were resistant to crumbling, presenting only minor (if any) tablet edge erosion after friability test. See, FIG. 6.
• E Purified water is used in the film coating process and is removed during processing
• h Represents 3% weight gain on the tablet core weight.
• Opadry White, Colorcon 33G28707 contains Hypromellose (Ph. Eur.), titanium dioxide (Ph. Eur.), and triacetin (Ph. Eur.).
• the actual amount of microcrystalline cellulose is based on a concomitant reduction such that the target core weight remains 600 mg b Ceolus UF-711 or equivalent
• E represents 4% weight gain on the tablet core weight.
• Opadry QX White, Colorcon 321A180025 contains GMCC type 1/mono- and diglycerides, polyethylene glycol polyvinyl alcohol graft copolymer, polyvinyl alcohol (partially hydrolyzed), talc, and titanium dioxide.
• FIG. 10 shows that storage under accelerated storage conditions significantly reduced the dissolution rate of 33% AG10 HC1 tablets.
• 66.7% AG10 HC1 tablets were also bottled and placed under accelerated storage conditions.
• FIG. 11 shows that 400 mg AG10 HC1 tablets did not show a reduction in dissolution rate after storage for 6 months.
• Both formulations of AG10 HC1 tablets were evaluated using the same dissolution method (USP 2 Apparatus (Paddles), 900 mL 0.1 N HC1, 75 RPM, 37°C) for release and for stability studies.
• the 66.7% AG10 HC1 tablet formulation was superior relative to the 33% AG10 HC1 tablet formulation in terms of dissolution rate after storage, indicating that the 66.7% AG10 HC1 tablet has improved storage capacity.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Inorganic Chemistry (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (21)

Applications Claiming Priority (2)

Publications (1)

Family

ID=69524257

Family Applications (1)

Country Status (23)

Cited By (1)

Families Citing this family (4)

Citations (3)

Family Cites Families (78)

• 2019
  • 2019-08-16 WO PCT/US2019/046789 patent/WO2020037189A1/en not_active Ceased
  • 2019-08-16 SM SM20250463T patent/SMT202500463T1/it unknown
  • 2019-08-16 PT PT198499485T patent/PT3836920T/pt unknown
  • 2019-08-16 LT LTEPPCT/US2019/046789T patent/LT3836920T/lt unknown
  • 2019-08-16 JP JP2021507989A patent/JP7469293B2/ja active Active
  • 2019-08-16 KR KR1020217007760A patent/KR20210046708A/ko not_active Ceased
  • 2019-08-16 MX MX2021001761A patent/MX2021001761A/es unknown
  • 2019-08-16 DK DK19849948.5T patent/DK3836920T3/da active
  • 2019-08-16 CA CA3104695A patent/CA3104695A1/en active Pending
  • 2019-08-16 US US16/542,737 patent/US11260047B2/en active Active
  • 2019-08-16 EA EA202190561A patent/EA202190561A1/ru unknown
  • 2019-08-16 BR BR112020026493-8A patent/BR112020026493A2/pt unknown
  • 2019-08-16 AU AU2019321583A patent/AU2019321583C1/en active Active
  • 2019-08-16 MA MA053238A patent/MA53238A/fr unknown
  • 2019-08-16 FI FIEP19849948.5T patent/FI3836920T3/fi active
  • 2019-08-16 HR HRP20251603TT patent/HRP20251603T1/hr unknown
  • 2019-08-16 TW TW108129285A patent/TWI834708B/zh active
  • 2019-08-16 EP EP19849948.5A patent/EP3836920B1/en active Active
  • 2019-08-16 EP EP25190457.9A patent/EP4647068A2/en active Pending
  • 2019-08-16 UA UAA202101319A patent/UA128256C2/uk unknown
  • 2019-08-16 SG SG11202101393PA patent/SG11202101393PA/en unknown
  • 2019-08-16 CN CN201980054507.6A patent/CN112804998A/zh active Pending
• 2021
  • 2021-02-03 CL CL2021000289A patent/CL2021000289A1/es unknown
  • 2021-02-16 IL IL280906A patent/IL280906B1/en unknown
• 2022
  • 2022-01-18 US US17/577,479 patent/US12005043B2/en active Active
• 2024
  • 2024-04-04 JP JP2024060790A patent/JP2024083460A/ja active Pending
• 2025
  • 2025-09-03 AU AU2025226697A patent/AU2025226697A1/en active Pending

Patent Citations (4)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events